Topics

Maintenance CC-486 Improves OS in Newly Diagnosed AML

19:58 EDT 12 Sep 2019 | OncLive

Maintenance therapy with CC-486 (oral azacitidine) led to a highly statistically significant and clinically meaningful improvement in overall survival compared with placebo in patients with newly diagnosed acute myeloid leukemia who achieved first complete response or CR with incomplete blood count recovery with induction therapy.

Original Article: Maintenance CC-486 Improves OS in Newly Diagnosed AML

NEXT ARTICLE

More From BioPortfolio on "Maintenance CC-486 Improves OS in Newly Diagnosed AML"

Quick Search